Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models.

MLA

Guo, Zhanfang, et al. “Evaluation of Copanlisib in Combination with Eribulin in Triple-Negative Breast Cancer Patient-Derived Xenograft Models.” Cancer Research Communications, vol. 4, no. 6, June 2024, pp. 1430–40. EBSCOhost, https://doi.org/10.1158/2767-9764.CRC-24-0047.

APA

Guo, Z., Luo, J., Mashl, R. J., Hoog, J., Maiti, P., Fettig, N., Davies, S. R., Aft, R., Held, J. M., Govindan, R., Ding, L., Li, S., von Morze, C., Wulf, G. M., Shoghi, K. I., & Ma, C. X. (2024). Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models. Cancer Research Communications, 4(6), 1430–1440. https://doi.org/10.1158/2767-9764.CRC-24-0047

Chicago

Guo, Zhanfang, Jingqin Luo, R Jay Mashl, Jeremy Hoog, Piyush Maiti, Nikki Fettig, Sherri R Davies, et al. 2024. “Evaluation of Copanlisib in Combination with Eribulin in Triple-Negative Breast Cancer Patient-Derived Xenograft Models.” Cancer Research Communications 4 (6): 1430–40. doi:10.1158/2767-9764.CRC-24-0047.